Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ABUS, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| AB-729 | Chronic Hepatitis b | Phase 2 · NCT04980482 | Completed |
| ARB-001467 | Hepatitis B, Chronic | Phase 2 · NCT02631096 | Completed |
| Imdusiran | Hepatitis B, Chronic | Phase 2 · NCT06245291 | Withdrawn |
| Peg-IFNα-2a | Chronic Hepatitis b | Phase 2 · NCT04980482 | Completed |
| Lipid Encapsulated Anti-PLK1 siRNA TKM-P | Hepatocellular Carcinoma | Phase 1/2 · NCT02191878 | Completed |
| Vebicorvir | Chronic Hepatitis B | Phase 2 · NCT04820686 | Terminated |
| Umbilical Cord Blood-derived CD16-expres | Chronic Hepatitis b | Phase 1 · NCT05960240 | Completed |
| AB-836 | Chronic Hepatitis | Phase 1 · NCT04775797 | Terminated |
| Nucleos(t)ide Analogue | Chronic Hepatitis b | Phase 1 · NCT05960240 | Completed |
| PRO-040201 | Hypercholesterolemia | Phase 1 · NCT00927459 | Terminated |
| TKM-100201 | Ebola Virus Infection | Phase 1 · NCT01518881 | Terminated |
| TKM-100802 for Injection | Ebola Virus Infection | Phase 1 · NCT02041715 | Terminated |
Also used in these trials (approved or third-party drugs, not ABUS's own candidates): Durvalumab, Entecavir.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ABUS holds $92.6M in cash and short-term investments (as of Jun 30, 2026) and burns about $7.1M/quarter from operations, an estimated runway of 39.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 10 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ABUS files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Matthew Gline Director, 10% owner |
Insider | 38,847,462 | 19.64% | 2025-02-24 |
| Roivant Sciences Ltd. | 5%+ holder (13D) | 38,847,462 | 19.64% | 2025-02-21 |
| Two Seas Capital LP | Institution (13G, 5%+) | 18,557,543 | 9.38% | 2026-03-31 |
| Morgan Stanley | Institution (13G, 5%+) | 17,387,398 | 8.79% | 2026-06-30 |
| Whitefort Capital Master Fund, LP | 5%+ holder (13G) | 15,794,261 | 7.98% | 2026-09-04 |
| Michael J. McElhaugh Interim President & CEO, Director · +718,800 options |
Insider | 1,658,003 | 0.84% | 2025-02-14 |
| Michael J. Sofia Chief Scientific Officer · +437,800 options |
Insider | 1,652,283 | 0.84% | 2024-02-01 |
| David C Hastings Chief Financial Officer · +815,800 options |
Insider | 249,824 | 0.13% | 2025-02-14 |
| Tuan Nguyen Chief Financial Officer · +1.40M options |
Insider | 159,963 | 0.08% | 2026-09-18 |
| Karen Sims Chief Medical Officer · +604,200 options |
Insider | 155,494 | 0.08% | 2025-02-14 |
| J. Christopher Naftzger General Counsel and CCO · +600,800 options |
Insider | 140,544 | 0.07% | 2025-02-14 |
| Lindsay Androski President and CEO, Director · +255,258 options |
Insider | 72,337 | 0.04% | 2026-09-18 |
Share count 197,847,835 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ABUS and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →